2 weeks Ago By ABMN Staff
Clearline Capital LP purchased a new stake in UiPath Inc. ( NYSE:PATH – Free Report ) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 142,000 shares of the healthcare company’s stock, valued at approximately $1,801,000.
A number of other institutional investors and hedge funds have also recently modified their holdings of PATH. PNC Financial Services Group Inc. lifted its position in shares of UiPath by 50.
1% during the 4th quarter. PNC Financial Services Group Inc. now owns 19,135 shares of the healthcare company’s stock valued at $475,000 after acquiring an additional 6,385 shares during the period.
Corient Private Wealth LLC boosted its position in shares of UiPath by 8.7% during the 4th quarter. Corient Private Wealth LLC now owns 34,480 shares of the healthcare company’s stock worth $856,000 after purchasing an additional 2,756 shares in the last quarter.
US Bancorp DE grew its stake in shares of UiPath by 15.9% in the 4th quarter. US Bancorp DE now owns 68,424 shares of the healthcare company’s stock valued at $1,700,000 after buying an additional 9,389 shares during the period.
Commerce Bank bought a new stake in UiPath in the 4th quarter valued at about $243,000. Finally, Nomura Asset Management Co. Ltd.
raised its stake in UiPath by 18.0% during the 4th quarter. Nomura Asset Management Co.
Ltd. now owns 100,500 shares of the healthcare company’s stock worth $2,496,000 after buying an additional 15,300 shares during the period. 62.
50% of the stock is currently owned by institutional investors. Insider Buying and Selling at UiPath In other news, CFO Ashim Gupta sold 47,671 shares of the firm’s stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $12.
07, for a total transaction of $575,388.97. Following the completion of the sale, the chief financial officer now owns 849,917 shares in the company, valued at approximately $10,258,498.
19. The sale was disclosed in a document filed with the SEC, which is available at the SEC website . Corporate insiders own 22.
37% of the company’s stock. Analysts Set New Price Targets Read Our Latest Report on PATH UiPath Trading Up 1.7 % Shares of PATH opened at $12.
80 on Friday. The stock has a 50 day moving average of $12.16 and a 200 day moving average of $15.
49. The company has a market capitalization of $7.04 billion, a price-to-earnings ratio of -80.
00 and a beta of 0.87. UiPath Inc.
has a 12 month low of $10.37 and a 12 month high of $27.87.
UiPath ( NYSE:PATH – Get Free Report ) last announced its earnings results on Thursday, September 5th. The healthcare company reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.
03 by $0.01. The firm had revenue of $316.
00 million during the quarter, compared to analyst estimates of $303.69 million. UiPath had a negative return on equity of 3.
98% and a negative net margin of 8.13%. The business’s revenue was up 10.
0% compared to the same quarter last year. During the same period last year, the firm posted ($0.09) EPS.
As a group, equities research analysts predict that UiPath Inc. will post -0.23 earnings per share for the current year.
UiPath Company Profile ( Free Report ) UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization. Recommended Stories Receive News & Ratings for UiPath Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UiPath and related companies with MarketBeat.
com's FREE daily email newsletter ..
